Trojan‐Horse Strategy Targeting the Gut‐Liver Axis Modulates Gut Microbiome and Reshapes Microenvironment for Orthotopic Hepatocellular Carcinoma Therapy

Bibliographic Details
Title: Trojan‐Horse Strategy Targeting the Gut‐Liver Axis Modulates Gut Microbiome and Reshapes Microenvironment for Orthotopic Hepatocellular Carcinoma Therapy
Authors: Haochen Yao, Sheng Ma, Juanjuan Huang, Xinghui Si, Ming Yang, Wantong Song, Guoyue Lv, Guoqing Wang
Source: Advanced Science, Vol 11, Iss 44, Pp n/a-n/a (2024)
Publisher Information: Wiley, 2024.
Publication Year: 2024
Collection: LCC:Science
Subject Terms: gut microbiota, hepatic inflammation, hepatocellular carcinoma, immunotherapy, oral nanomedicine, Science
More Details: Abstract Reversing the hepatic inflammatory and immunosuppressive microenvironment caused by gut microbiota‐derived lipopolysaccharides (LPS), accumulating to the liver through the gut‐liver axis, is crucial for suppressing hepatocellular carcinoma (HCC) and metastasis. However, synergistically manipulating LPS‐induced inflammation and gut microbiota remains a daunting task. Herein, a Trojan‐horse strategy is proposed using an oral dextran‐carbenoxolone (DEX‐CBX) conjugate, which combines prebiotic and glycyrrhetinic acid (GA) homologs, to targeted delivery GA to HCC through the gut‐liver axis for simultaneous modulation of hepatic inflammation and gut microbiota. In the orthotopic HCC model, a 95–45% reduction in the relative abundances of LPS‐associated microbiota is observed, especially Helicobacter, caused by DEX‐CBX treatment over phosphate‐buffered saline (PBS) treatment. Notably, a dramatic increase (37‐fold over PBS) in the abundance of Akkermansia, which is known to strengthen systemic immune response, is detected. Furthermore, DEX‐CBX significantly increased natural killer T cells (5.7‐fold) and CD8+ T cells (3.9‐fold) as well as decreased M2 macrophages (59% reduction) over PBS treatment, resulting in a tumor suppression rate of 85.4%. DEX‐CBX is anticipated to offer a novel strategy to precisely modulate hepatic inflammation and the gut microbiota to address both the symptoms and root causes of LPS‐induced immunosuppression in HCC.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2198-3844
Relation: https://doaj.org/toc/2198-3844
DOI: 10.1002/advs.202310002
Access URL: https://doaj.org/article/77ed13ea08cb43fd86f4092c8206461e
Accession Number: edsdoj.77ed13ea08cb43fd86f4092c8206461e
Database: Directory of Open Access Journals
More Details
ISSN:21983844
DOI:10.1002/advs.202310002
Published in:Advanced Science
Language:English